--- title: "LLY Eli Lilly" canonical: "https://supercyclehq.com/stock/eli-lilly" type: "stock" dataAsOf: "2026-11-06" ticker: "LLY" license: "Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset." disclaimer: "Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI." --- # Eli Lilly (LLY) Eli Lilly is one of the world's largest pharmaceutical companies. ## AI Exposure Score **10/100, Peripheral.** Eli Lilly sells pharmaceuticals, led by GLP-1 drugs, and applies AI to discovery, trial design, and manufacturing. AI may speed the pipeline and it has partnered with AI drug discovery firms, but the value driver is drug demand, not AI. ## Quote | Field | Value | | --- | --- | | Price (EOD close) | $1,354.00 | | Change 1d | -0.79% | | Change 7d | -4.48% | | Change 30d | +15.77% | | Change 1y | +47.40% | | 52-week high | $1,417.99 | | 52-week low | $848.53 | | Market cap | $1.21T | | P/E | 43.95 | | EPS | $30.81 | | Next earnings | 2026-10-29 | Quote as of 2026-11-06. ## Company | Field | Value | | --- | --- | | Exchange | NYSE | | Sector | Healthcare | | Headquarters | Indianapolis, Indiana | | CEO | David A. Ricks | | Employees | 50,000 | | Website | https://www.lilly.com | | Buildout layers | [AI Healthcare](https://supercyclehq.com/category/ai-healthcare), [Foundation Models](https://supercyclehq.com/category/foundation-models) | ## What the company does Eli Lilly is one of the world's largest pharmaceutical companies. It makes money selling prescription drugs, led by its GLP-1 medicines for diabetes and weight loss, across global markets. AI is now part of what it builds, not just how it works. It trains its own foundation models for biology and chemistry on LillyPod, an in-house AI supercomputer, runs a co-innovation lab with NVIDIA aimed at frontier models for drug discovery, and offers those models to smaller biotechs through TuneLab, a platform that lets partners use them without exposing their own data. Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly trades on the NYSE and employs about 50,000 people. ## Role in the AI buildout Eli Lilly sits in the AI Healthcare and Foundation Models layers of the buildout. It is unusual among large pharma in training its own biology and chemistry foundation models, running the supercomputer they are trained on, and putting them in outside hands through TuneLab rather than keeping them internal. Those tools could compress the long timelines of drug development. The value driver is still drug demand, above all its GLP-1 franchise, so AI is an accelerant for a pharma giant rather than its engine. ## Tracked investors holding it (13F) | Investor | Fund | Position value | Portfolio % | Change | Period | | --- | --- | --- | --- | --- | --- | | [Ray Dalio](https://supercyclehq.com/investors/ray-dalio) | Bridgewater Associates | $104.4M | 0.43% | increased | 2026-06-30 | | [Cathie Wood](https://supercyclehq.com/investors/cathie-wood) | ARK Investment Management | $92.7M | 0.60% | increased | 2026-06-30 | | [George Soros](https://supercyclehq.com/investors/george-soros) | Soros Fund Management | $26.6M | 0.35% | unchanged | 2026-06-30 | | [Stanley Druckenmiller](https://supercyclehq.com/investors/stanley-druckenmiller) | Duquesne Family Office | $14.8M | 0.34% | new | 2026-06-30 | ## Recent news - [Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly](https://finance.yahoo.com/m/3eaa7d18-56f8-336a-a6a8-2cb209834b70/hims-%26-hers-surges-on.html?.tsrc=rss) (source, 2026-11-06) - [Sector Update: Healthcare Stocks Edge Lower Late Afternoon](https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-edge-lower-205338223.html?.tsrc=rss) (source, 2026-11-06) - [Eli Lilly Picks Hims & Hers to Sell Its Obesity Drugs, Days Before Hims Reports](https://www.tikr.com/blog/eli-lilly-picks-hims-hers-to-sell-its-obesity-drugs-days-before-hims-reports?ref=yahoofinance&tlnk=yf-261106-2f783gv8&.tsrc=rss) (source, 2026-11-06) - [Eli Lilly Strikes Surprising Deal With Hims & Hers](https://finance.yahoo.com/healthcare/articles/eli-lilly-strikes-surprising-deal-192531796.html?.tsrc=rss) (source, 2026-11-06) - [Eli Lilly (LLY) Highlights ACR Data, Is The Stock Still 8% Undervalued?](https://finance.yahoo.com/markets/stocks/articles/eli-lilly-lly-highlights-acr-191429644.html?.tsrc=rss) (source, 2026-11-06) ## FAQ ### What does Eli Lilly do? Eli Lilly sells prescription drugs globally, led by its GLP-1 medicines for diabetes and weight loss. It applies AI across drug discovery, clinical trials, and manufacturing. ### How is Eli Lilly exposed to AI? As an adopter. AI may speed its pipeline and it has partnered with AI drug discovery firms, but drug demand drives the business. Supercycle rates it an AI Exposure Score of 10 out of 100. ### What are Eli Lilly's main AI efforts? An AI drug discovery platform, clinical trial optimization tools, manufacturing AI for scaling production, and precision medicine machine learning for matching treatments to patients. ### Is LLY a pure play AI stock? No. Eli Lilly is a pharmaceutical company whose value rides drug franchises like GLP-1s. AI supports the pipeline, and its AI Exposure Score of 10 out of 100 reflects that supporting role. ### Where is Eli Lilly based and who leads it? Eli Lilly is headquartered in Indianapolis, Indiana, and is led by CEO David Ricks. The company was founded in 1876 and employs about 50,000 people. --- Source: https://supercyclehq.com/stock/eli-lilly. Data as of 2026-11-06. Prices are end-of-day closes, never live. Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI. Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset.